R2 김형오 / Pf. 김시영
Recent results Presence of extensive lymphocytic infiltration in early stage breast cancer Good prognosis High response rates to neoadjuvant chemotherapy TIL(Tumor-infiltrating lymphocytes) Shown to be a good prognostic indicator ▪ Only in highly proliferative breast tumor ▪ Not routine
Recent concept Cell death induced by chemotherapies can promote permanant antitumor immunity ▪ Anthracyclines, oxaliplatin, gemcitabine etc ▪ May be critical for long-lasting remission BIG(Breast International Group) study Extensive follow up Randomized Prospectively planned
To examine the hypothesis Increased lymphocytic infiltration would be associated with good prognosis Benefit from immunogenic chemotherapy in selected breast cancer subtypes
BIG Multicenter, randomized, prospective, phase III 2887 patients, LN (+), 1998~2001 ▪ A1 : Sequential control ▪ CMF 3 cycle -> doxorubicin 75mg/m2, 4 cycles ▪ A2 : Concurrent control ▪ CMF 3 cycle -> Doxorubicin 60mg/m2 4 cycles + cyclophosphamide 600mg/m2 ▪ B : Sequential docetaxel ▪ CMF 3 cycle -> docetaxel 100mg/m2 -> doxorubicin 75mg/m2 ▪ C : Concurrent doxetaxel ▪ CMF 3 cycle -> docetaxel 75mg/m2 + doxorubicin 50mg/m2 -> 2009 samples analyzed(69.6%)
Definitions Intratumoral lymphocytic infiltration ▪ Percentage of mononuclear cells within the epithelium of the invasive tumor cell nests Stromal lymphocytic infiltration ▪ Percentage of tumor stroma containing infiltrating lymphocytes Disease free survival(DFS) ▪ Date of random assignment ~ 1 st relapse, 2 nd primary, death Overall survival(OS) ▪ Date of random assignment ~ date of death with any cause Lymphocyte predominant breast cancer ▪ >=50% infiltration of stromal or intratumoral lymphocytic infiltration
Group subtypes ER, HER2 ▪ ER negative / HER2 negative ▪ HER2 overexpressing ▪ ER positive / HER 2 negative
TILs and pathologics association TILs(stromal/intratumoral) were associated with ▪ Infiltrating ductal histology, (P<0.001, p=0.048) ▪ High histologic grade, (p<0.001, p<0.001) ▪ Hormone receptor negativity, (P<0.001, p<0.001) ▪ Not associated with age, menopausal state, increasing lymph node involvement, tumor size Median percentage ▪ Infiltration of intratumoral lymphocytes : 2% ▪ Stromal lymphocytes : 10%
10% increment of infiltration stromal, 15% reduction of risk for recurrence or death (17% risk of death) intratumoral 17% reduction of risk for recurrence or death (27% risk of death)
HER2(+), anthracycline only HER2(+), anthracycline, docetaxel
Increasing lymphocytic infiltration of the tumor and stroma Associated with good prognosis Only in ER(-)/HER2(-) subgroup Interaction between increasing stromal infiltration and chemotherapy regimen was seen only in the HER2(+) Strengths Size, Randomization, Long-term follow-up, Two independent pathologic assessment Increasing lymphocytic infiltration is a strong prognostic factor for the ER(-)/HER2(-) BC subtype